215 related articles for article (PubMed ID: 32172935)
1. Newborn screening for CF in France: An exemplary national experience.
Audrézet MP; Munck A
Arch Pediatr; 2020 Feb; 27 Suppl 1():eS35-eS40. PubMed ID: 32172935
[TBL] [Abstract][Full Text] [Related]
2. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population.
Sommerburg O; Lindner M; Muckenthaler M; Kohlmueller D; Leible S; Feneberg R; Kulozik AE; Mall MA; Hoffmann GF
J Inherit Metab Dis; 2010 Oct; 33(Suppl 2):S263-71. PubMed ID: 20714932
[TBL] [Abstract][Full Text] [Related]
3. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.
Comeau AM; Parad RB; Dorkin HL; Dovey M; Gerstle R; Haver K; Lapey A; O'Sullivan BP; Waltz DA; Zwerdling RG; Eaton RB
Pediatrics; 2004 Jun; 113(6):1573-81. PubMed ID: 15173476
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive CFTR gene analysis of the French cystic fibrosis screened newborn cohort: implications for diagnosis, genetic counseling, and mutation-specific therapy.
Audrézet MP; Munck A; Scotet V; Claustres M; Roussey M; Delmas D; Férec C; Desgeorges M
Genet Med; 2015 Feb; 17(2):108-16. PubMed ID: 25122143
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of 47,213 infants in neonatal screening for cystic fibrosis, using pancreatitis-associated protein and immunoreactive trypsinogen assays].
Barthellemy S; Maurin N; Roussey M; Férec C; Murolo S; Berthézène P; Iovanna JL; Dagorn JC; Sarles J
Arch Pediatr; 2001 Mar; 8(3):275-81. PubMed ID: 11270251
[TBL] [Abstract][Full Text] [Related]
6. Cystic fibrosis newborn screening in Denmark: Experience from the first 2 years.
Skov M; Baekvad-Hansen M; Hougaard DM; Skogstrand K; Lund AM; Pressler T; Olesen HV; Duno M
Pediatr Pulmonol; 2020 Feb; 55(2):549-555. PubMed ID: 31682332
[TBL] [Abstract][Full Text] [Related]
7. Current Status of Genetic Diagnosis Laboratories and Frequency of Genetic Variants Associated with Cystic Fibrosis through a Newborn-Screening Program in Turkey.
Bozdogan ST; Mujde C; Boga I; Sonmezler O; Hanta A; Rencuzogullari C; Ozcan D; Altintas DU; Bisgin A
Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33572515
[TBL] [Abstract][Full Text] [Related]
8. Diagnosing cystic fibrosis in newborn screening in Poland - 15 years of experience.
Sands D; Zybert K; Mierzejewska E; Ołtarzewski M
Dev Period Med; 2015; 19(1):16-24. PubMed ID: 26003066
[TBL] [Abstract][Full Text] [Related]
9. A model-based economic evaluation of four newborn screening strategies for cystic fibrosis in Flanders, Belgium.
Schmidt M; Werbrouck A; Verhaeghe N; De Wachter E; Simoens S; Annemans L; Putman K
Acta Clin Belg; 2020 Jun; 75(3):212-220. PubMed ID: 31007159
[No Abstract] [Full Text] [Related]
10. Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis.
Sontag MK; Lee R; Wright D; Freedenberg D; Sagel SD
J Pediatr; 2016 Aug; 175():150-158.e1. PubMed ID: 27131402
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm.
Parad RB; Comeau AM
J Pediatr; 2005 Sep; 147(3 Suppl):S78-82. PubMed ID: 16202789
[TBL] [Abstract][Full Text] [Related]
12. Optimization of the French cystic fibrosis newborn screening programme by a centralized tracking process.
Munck A; Delmas D; Audrézet MP; Lemonnier L; Cheillan D; Roussey M
J Med Screen; 2018 Mar; 25(1):6-12. PubMed ID: 28454512
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of newborn screening for cystic fibrosis: a simulation study.
Nshimyumukiza L; Bois A; Daigneault P; Lands L; Laberge AM; Fournier D; Duplantie J; Giguère Y; Gekas J; Gagné C; Rousseau F; Reinharz D
J Cyst Fibros; 2014 May; 13(3):267-74. PubMed ID: 24238947
[TBL] [Abstract][Full Text] [Related]
14. A survey of newborn screening for cystic fibrosis in Europe.
Southern KW; Munck A; Pollitt R; Travert G; Zanolla L; Dankert-Roelse J; Castellani C;
J Cyst Fibros; 2007 Jan; 6(1):57-65. PubMed ID: 16870510
[TBL] [Abstract][Full Text] [Related]
15. Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing.
Rock MJ; Hoffman G; Laessig RH; Kopish GJ; Litsheim TJ; Farrell PM
J Pediatr; 2005 Sep; 147(3 Suppl):S73-7. PubMed ID: 16202788
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of specificity and sensitivity of IRT/IRT protocol in the cystic fibrosis newborn screening program: 6-year experience of three tertiary centers.
Ramasli Gursoy T; Asfuroglu P; Sismanlar Eyuboglu T; Aslan AT; Yilmaz AI; Unal G; Kibar BS; Pekcan S; Hangul M; Kose M; Budakoglu II; Acican D
Eur J Pediatr; 2023 Mar; 182(3):1067-1076. PubMed ID: 36565324
[TBL] [Abstract][Full Text] [Related]
17. Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population.
Corbetta C; Seia M; Bassotti A; Ambrosioni A; Giunta A; Padoan R
J Med Screen; 2002; 9(2):60-3. PubMed ID: 12133923
[TBL] [Abstract][Full Text] [Related]
18. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis.
Sarles J; Berthézène P; Le Louarn C; Somma C; Perini JM; Catheline M; Mirallié S; Luzet K; Roussey M; Farriaux JP; Berthelot J; Dagorn JC
J Pediatr; 2005 Sep; 147(3):302-5. PubMed ID: 16182665
[TBL] [Abstract][Full Text] [Related]
19. Cystic fibrosis newborn screening: using experience to optimize the screening algorithm.
Hale JE; Parad RB; Dorkin HL; Gerstle R; Lapey A; O'Sullivan BP; Spencer T; Yee W; Comeau AM
J Inherit Metab Dis; 2010 Oct; 33(Suppl 2):S255-61. PubMed ID: 20521170
[TBL] [Abstract][Full Text] [Related]
20. Prospective and parallel assessments of cystic fibrosis newborn screening protocols in the Czech Republic: IRT/DNA/IRT versus IRT/PAP and IRT/PAP/DNA.
Krulišová V; Balaščaková M; Skalická V; Piskáčková T; Holubová A; Paděrová J; Křenková P; Dvořáková L; Zemková D; Kračmar P; Chovancová B; Vávrová V; Stambergová A; Votava F; Macek M
Eur J Pediatr; 2012 Aug; 171(8):1223-9. PubMed ID: 22581207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
